Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.620 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
39 40 Next >
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 5, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 1.60% at $1.27 LOSERS: 
Via Benzinga
Cybin Subsidiary Achieves Milestone
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.06% at $14.18 
Via Benzinga
Cybin's (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
Via Investor Brand Network
3 Psychedelic Stocks to Buy for Oregon’s Magic Mushroom Bill
Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. 
Via InvestorPlace
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.26% at $0.86 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement Of Kernel Flow(R) Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
Via Investor Brand Network
March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%
An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the... 
Via Talk Markets
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.38% at $0.27 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development
Via Investor Brand Network
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain
The first study visit to measurethe psychedelic effects of ketamine in the cerebral cortex blood flowis underway, ... 
Via Benzinga
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 4.22% at $0.46 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone In CYB003 Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From March 29, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 9.05% at $5.42 
Via Benzinga
Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder
Cybin Inc.(NYSE: CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. ... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program
Via Investor Brand Network
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
From Cybin Inc.
Via Business Wire
Mindset Pharma, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 8.24% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 25, 2022
GAINERS: Allied (OTC: 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement
Via Investor Brand Network
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.